Updates In Ophthalmology
Advances in Treatment of Exudative Retinal Vascular Disorders: Novel Mechanisms of Action and New Delivery Systems to Achieve Vascular Stability While Reducing Treatment Burden
Speakers: Carl Regillo, MD, FASRS, Director of Retina ServiceDante Pieramici, MD, Director
Duration: 60 minutes
Presented on: October 26, 2022
Carl Regillo, MD, FASRS
Carl Regillo, MD, FASRS
Director of Retina ServiceCarl Regillo, MD, FASRS, is the Director of Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University in Philadelphia. He is the founder and former Director of the Wills Eye Clinical Retina Research Unit, former Chairman of the American Academy of Ophthalmology Retina Basic and Clinical Science Course, and prior Director of the Wills Eye Retina Fellowship. Additionally, Dr. Regillo has authored over 200 publications along with over 20 book chapters and nine major books. He has been an investigator on numerous major clinical trials developing new treatments for retinal disorders such as macular degeneration and diabetic retinopathy. Furthermore, Dr. Regillo was also listed among the top 150 ophthalmologists in the US by Newsweek in 2021.
Dante Pieramici, MD
Dante Pieramici, MD
DirectorDante Pieramici, MD, is the Director of the California Retina Research Foundation, a partner of the California Retina Consultants, and serves on the leadership board of the Retina Consultants of America. Dr. Pieramici has published over 125 peer reviewed papers, 16 book chapters, and has edited 3 books on retinal diseases. His research interests include clinical and basic science projects aimed at a better understanding of the underlying pathophysiology of ocular diseases, to improve treatments for patients with age-related macular degeneration, diabetic retinopathy, retinal vascular diseases, and severe ocular injuries. Dr. Pieramici has received the Achievement Award from the American Academy of Ophthalmology and Senior Honor Award from the American Society of Retinal Specialists.
Advances in Treatment of Exudative Retinal Vascular Disorders:
Novel Mechanisms of Action and New Delivery Systems to Achieve Vascular Stability While Reducing Treatment Burden
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Genentech, a member of the Roche Group.
DATE OF LIVE ACTIVITYWednesday, October 26, 2022 from 7:30 – 8:30pm ET
TARGET AUDIENCEThe educational design of this activity addresses the needs of ophthalmologists who diagnose and treat patients with neovascular retinal diseases, including nAMD, DME, and/or RVO, and other clinicians involved in the management of patients with neovascular retinal diseases.
STATEMENT OF NEED/PROGRAM OVERVIEWWhile the prevalence of neovascular eye diseases is increasing, anti-vascular endothelial growth factor (VEGF) agents, which have repeatedly been shown to preserve or improve visual acuity, have dramatically improved the outlook for patients, their families, and their caregivers. However, early anti-VEGF agents approved for retinal vascular disorders – e.g., neovascular (wet) age-related macular degeneration, diabetic macular edema/diabetic retinopathy, and retinal vein occlusion – are limited by the need for frequent intravitreal injections and the potential for adverse events.
Join a panel of expert ophthalmologists to review the efficacy and safety of emerging options for neovascular retinal diseases, including new anti-angiogenesis agents and novel intravitreal delivery systems. Panelists will discuss the time commitments and logistical challenges faced by patients who require intravitreal injections. Experts will then analyze the most current evidence on new options to manage retinal disorders and explore their ability to reduce the treatment burden imposed on patients and caregivers and improve patients’ quality of life.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Recognize the burden and concerns that retinal vascular diseases (AMD, DME/DR, and RVO), as well as their traditional treatments with anti-VEGF agents, pose for patients and their caregivers
- Summarize current data on the efficacy and safety of new and emerging treatment options and delivery system for retinal vascular disorders, including dual-acting bispecific monoclonal antibodies that block VEGF and inhibit angiopoietin 2
- Discuss the place of new agents and delivery devices in the care of patients with vascular retinal diseases
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 60 minutes to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF CONFLICTS OF INTERESTGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Dante J. Pieramici, MD
California Retina Research Foundation
Partner, California Retina Consultants
Member, Retina Consultants of America
Consultant: Adverum, Clearside, Genentech, Ophthea Perceive, Regeneron, Regenx Bio, and Unity
Grant/Research Support: Adverum, Apellis, Clearside, Genentech, Greybug, Kodiac, NGM, Ocular, Ocular Therapeutic, Oculis, Ophthea, Oxurion, Perceive, Regeneron, Regenx Bio, Stealth, Unity, and Valo
Carl Regillo, MD
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, Eyepoint, Genentech, Graybug, Iveric, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, RegenXBio, Stealth, Thea, and Zeiss
Grant/Research Support: Adverum, Allergan, Annexon, Apellis, Astellis, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Opthea, Regeneron, and RegenXBio
Stockholder: Iveric and Ocugen
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Eve Wilson, PhD, FACEHP Nothing to disclose Stephanie Puccio Nothing to disclose
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Technical Support:For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.